Does early detection of atrial fibrillation reduce the risk of thromboembolic events? Rationale and design of the Heartline study - 06/04/23
, Steven Steinhubl, MD b, Dhanunjaya Lakkireddy, MD c, Mintu P. Turakhia, MD, MAS d, e, Rod Passman, MD, MSCE f, W. Schuyler Jones, MD g, T. Jared Bunch, MD h, Anne B. Curtis, MD i, Eric D. Peterson, MD, MPH g, Jeremy Ruskin, MD j, Leslie Saxon, MD k, Michael Tarino, MBA l, Khaldoun G. Tarakji, MD, MPH m, Nassir Marrouche, MD n, Mithun Patel, MD o, Ante Harxhi, MD p, Simrati Kaul, PhD p, Janeta Nikolovski, PhD q, Stephanie Juan, MPH p, Kevin Wildenhaus, PhD q, C.V. Damaraju, PhD q, John A. Spertus, MD, MPH rthe Heartline Steering Committee
ABSTRACT |
Background |
The impact of using direct-to-consumer wearable devices as a means to timely detect atrial fibrillation (AF) and to improve clinical outcomes is unknown.
Methods |
Heartline is a pragmatic, randomized, and decentralized application-based trial of US participants aged ≥65 years. Two randomized cohorts include adults with possession of an iPhone and without a history of AF and those with a diagnosis of AF taking a direct oral anticoagulant (DOAC) for ≥30 days. Participants within each cohort are randomized (3:1) to either a core digital engagement program (CDEP) via iPhone application (Heartline application) and an Apple Watch (Apple Watch Group) or CDEP alone (iPhone-only Group). The Apple Watch Group has the watch irregular rhythm notification (IRN) feature enabled and access to the ECG application on the Apple Watch. If an IRN notification is issued for suspected AF then the study application instructs participants in the Apple Watch Group to seek medical care. All participants were “watch-naïve” at time of enrollment and have an option to either buy or loan an Apple Watch as part of this study. The primary end point is time from randomization to clinical diagnosis of AF, with confirmation by health care claims. Key secondary endpoint are claims-based incidence of a 6-component composite cardiovascular/systemic embolism/mortality event, DOAC medication use and adherence, costs/health resource utilization, and frequency of hospitalizations for bleeding. All study assessments, including patient-reported outcomes, are conducted through the study application. The target study enrollment is approximately 28,000 participants in total; at time of manuscript submission, a total of 26,485 participants have been enrolled into the study.
Conclusion |
The Heartline Study will assess if an Apple Watch with the IRN and ECG application, along with application-facilitated digital health engagement modules, improves time to AF diagnosis and cardiovascular outcomes in a real-world environment.
Trial registration |
ClinicalTrials.gov Identifier: NCT04276441.
Le texte complet de cet article est disponible en PDF.Plan
Vol 259
P. 30-41 - mai 2023 Retour au numéro
Article précédent
- Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial): Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial
- Carl Johan Malm, Joakim Alfredsson, David Erlinge, Tomas Gudbjartsson, Jarmo Gunn, Stefan James, Christian H. Møller, Susanne J. Nielsen, Ulrik Sartipy, Theis Tønnessen, Anders Jeppsson
- A Randomized Trial of Lenient Versus Strict Arm Instruction Post Cardiac Device Surgery (LENIENT)
- Mehrdad Golian, Mouhannad M. Sadek, Alper Aydin, Darryl Davis, Martin Green, Andres Klein, Girish M. Nair, Pablo Nery, F. Daniel Ramirez, Calum Redpath, Simon P. Hansom, George A. Wells, David H. Birnie
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?